CCHT(SZ:000661) Zheng Quan Ri Bao·2025-09-17 13:06Core Insights - Changchun High-tech announced a collaboration with Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China [2] - The partnership includes exclusive rights for Changchun Jin Sai Pharmaceutical Co., Ltd. to market three products developed by ALK in mainland China [2] Company Summary - Changchun High-tech's subsidiary, Changchun Jin Sai Pharmaceutical, will work with ALK-Abelló A/S on AIT products targeting house dust mites (HDM) [2] - The collaboration aims to leverage ALK's expertise in immunotherapy to enhance product offerings in the Chinese market [2] Industry Summary - The partnership signifies a growing trend in the immunotherapy sector, particularly in addressing allergic conditions in China [2] - The exclusive rights to market ALK's products may strengthen Changchun High-tech's position in the competitive pharmaceutical landscape [2]